
Eli Lilly (LLY) Stock Forecast & Price Target
Eli Lilly (LLY) Analyst Ratings
Bulls say
Eli Lilly is well positioned for future growth due to its strong portfolio of key products in the neuroscience, cardiometabolic, cancer, and immunology areas. The company's strategic focus on diversification and expansion into international markets is expected to result in strong revenue growth in the coming years. With impressive prescription trends and increasing market share, Lilly's 2026, 2027, and 2028 sales and earnings estimates outpace consensus expectations. The launch of Foundayo and the GLP-1 Bridge program for Medicare, along with strong performance in ex-US markets, further support a positive outlook for the company. Additionally, Lilly's focus on diversity, equity, and inclusion in clinical trials is a key factor in its long-term success and mitigates regulatory risks.
Bears say
Eli Lilly is a market leader in neuroscience, cardiometabolic, and immunology, with a diverse portfolio of key products. However, steep pricing pressures, underwhelming TRx growth in key products, and increased competition in the obesity landscape pose significant risks to the company's success. The company has shown strong revenue growth and a solid 2Q performance, but questions around GLP-1 demand and pricing remain. With a broad ex-CVM pipeline and a potential for a sustainable pricing model, the company's stock may have further upside potential, but it should be closely monitored due to potential headwinds.
This aggregate rating is based on analysts' research of Eli Lilly and is not a guaranteed prediction by Public.com or investment advice.
Eli Lilly (LLY) Analyst Forecast & Price Prediction
Start investing in Eli Lilly (LLY)
Order type
Buy in
Order amount
Est. shares
0 shares